Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROPOFOL vs AMIDATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Propofol enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to increased chloride conductance, neuronal hyperpolarization, and anesthetic effects. It also inhibits N-methyl-D-aspartate (NMDA) receptors and modulates calcium influx via L-type calcium channels.
AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.
Induction and maintenance of general anesthesia,Sedation for intubated, mechanically ventilated patients in the ICU,Procedural sedation (e.g., during diagnostic or therapeutic procedures),Treatment of refractory status epilepticus (off-label),Management of severe agitation or delirium (off-label)
Induction of general anesthesia,Maintenance of anesthesia (as part of balanced anesthesia),Procedural sedation (off-label),Rapid sequence intubation (RSI) (off-label)
Induction: 2-2.5 mg/kg IV bolus. Maintenance: 25-75 mcg/kg/min IV infusion. For sedation: 25-100 mcg/kg/min IV.
0.2-0.6 mg/kg IV bolus for induction of anesthesia.
Terminal elimination half-life: 4-7 hours (after prolonged infusion, context-sensitive half-life increases up to 60 minutes after 8-hour infusion).
Terminal elimination half-life: 2.5–4 hours (adults); 1–2 hours (children); Prolonged in hepatic impairment or with continuous infusion.
Primarily hepatic via conjugation to glucuronide and sulfate; also metabolized by CYP2B6 and CYP2C9. Metabolites are renally excreted.
Primarily hepatic via hydrolysis by esterases to inactive metabolites (carboxylic acid and ethanol); also undergoes glucuronidation.
Renal: <1% unchanged; hepatic metabolism to inactive glucuronide and sulfate conjugates, excreted renally (≈88%) and fecally (≈1-2%).
Renal: <5% unchanged; Hepatic metabolism to carboxylic acid metabolite (inactive); Metabolite renally eliminated; Fecal: negligible.
95-99% bound primarily to albumin (≈48%) and alpha-1-acid glycoprotein (≈50%), with minor binding to lipoproteins.
97–98% bound; Primary binding to albumin; Reduced binding in neonates and hepatic/renal disease.
Initial Vd: 0.2-0.4 L/kg (central compartment); steady-state Vd: 2-10 L/kg (extensive tissue distribution).
Vd: 2.5–4.5 L/kg; Large Vd indicates extensive tissue distribution (highly lipophilic).
IV: 100%; enteral: negligible due to first-pass metabolism; oral bioavailability <1%.
IV: 100%; IM: >90%; Rectal: ~50% (variable).
No dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, use with caution due to propylene glycol accumulation, monitor for metabolic acidosis.
No adjustment required; pharmacokinetics unchanged in renal impairment.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Avoid use or reduce by 75% due to prolonged clearance and risk of hypotension.
No specific guidelines; use with caution in severe hepatic impairment due to potential for decreased clearance.
Induction: 2.5-3.5 mg/kg IV over 30 sec. Maintenance: 125-300 mcg/kg/min for age <3 years; 100-200 mcg/kg/min for age 3-12 years. For sedation: 25-100 mcg/kg/min.
3-5 mg/kg IV bolus for induction in children; lower doses may be sufficient.
Reduce induction dose to 1-1.5 mg/kg IV; decrease infusion rate by 20-50% due to reduced clearance and increased sensitivity.
Reduce dose to 0.15-0.3 mg/kg IV bolus due to increased sensitivity and decreased clearance.
No FDA black box warnings.
None
Hypotension and bradycardia: may require fluid resuscitation or vasopressors,Respiratory depression and apnea: must have airway management equipment available,Propofol infusion syndrome (PRIS): rare but fatal with high doses >4 mg/kg/hr for >48 hours; characterized by metabolic acidosis, rhabdomyolysis, hyperkalemia, and cardiac failure,Risk of pancreatitis: monitor lipase if symptoms develop,Abrupt discontinuation may cause withdrawal symptoms after prolonged use,Not recommended for use in patients with propofol allergy or egg/soybean oil hypersensitivity (formulation contains egg lecithin and soybean oil)
Suppresses adrenal steroidogenesis via reversible inhibition of 11-beta-hydroxylase (cortisol and aldosterone synthesis) – risk of adrenal insufficiency, especially with prolonged infusion or multiple doses,May cause myoclonus (involuntary muscle movements) during induction,Can produce hypotension less frequently than other induction agents, but still possible,Use caution in patients with adrenal suppression, sepsis, or hepatic impairment,May cause pain on injection (use large vein or consider pretreatment)
Hypersensitivity to propofol or any component of the formulation (including egg lecithin, soybean oil, or disodium edetate),Patients with severe lipid metabolism disorders (e.g., pancreatitis with hypertriglyceridemia),Not for use in general anesthesia in obstetrics (crosses placenta; may cause neonatal depression),Relative: hypovolemia, hemodynamic instability, increased intracranial pressure (use with caution)
Known hypersensitivity to etomidate or any component of the formulation,Patients with known adrenal insufficiency (relative contraindication due to potential for further suppression)
No specific food restrictions. However, propofol is formulated in a lipid emulsion containing soybean oil and egg lecithin, which may interact with high-fat meals theoretically but not clinically significant. Avoid alcohol for 24 hours post-procedure due to additive sedative effects.
None known. However, because etomidate is administered intravenously in a fasting state prior to procedures, food intake is restricted per standard pre-procedural fasting guidelines (typically NPO for 6-8 hours).
First trimester: Propofol is not associated with major congenital malformations based on limited human data, but animal studies show developmental toxicity at high doses. Second trimester: No clear evidence of fetal harm. Third trimester: Use may cause neonatal respiratory depression, hypotonia, and neurobehavioral effects; risk of fetal bradycardia and hypoxia. Propofol crosses the placenta rapidly.
Pregnancy Category D. First trimester: Associated with congenital anomalies (e.g., neural tube defects, cardiovascular malformations) based on human data. Second/third trimesters: May cause fetal CNS depression, hypotonia, and respiratory depression with chronic use. Avoid in pregnancy unless benefit outweighs risk.
Propofol is excreted into breast milk in very low concentrations, with an estimated M/P ratio of 1.2-1.5. The relative infant dose is <0.1% of weight-adjusted maternal dose. Consider discarding milk for 24 hours after administration due to potential sedative effects on the infant.
Excreted in breast milk; M/P ratio 0.5-0.8. Potential for infant sedation and respiratory depression. Caution advised; monitor infant for drowsiness and feeding difficulties. Consider alternative therapies.
Pregnancy increases volume of distribution and clearance of propofol by 20-50%, primarily due to increased cardiac output and hepatic blood flow. Induction doses may need to be increased by 15-30% to achieve desired effect. Maintenance infusion rates may also require upward titration.
No standard dose adjustment recommended; however, increased clearance during pregnancy may necessitate higher doses for efficacy. Monitor therapeutic response and adjust as needed. Avoid use in first trimester if possible.
Propofol causes dose-dependent respiratory depression and apnea; always have airway equipment ready. It reduces cerebral metabolic rate and intracranial pressure, making it useful for neuroanesthesia. Pain on injection is common, particularly in small veins; consider lidocaine pretreatment. Propofol infusion syndrome (PRIS) is a rare but fatal complication with prolonged high-dose infusions (>48h, >4 mg/kg/h), characterized by lactic acidosis, rhabdomyolysis, and cardiac failure. Avoid in patients with egg or soy allergy due to lipid emulsion. Use the lower dose for elderly or hemodynamically unstable patients. Monitor triglyceride levels with prolonged use.
Amidate (etomidate) is an ultra-short acting non-barbiturate hypnotic used for induction of anesthesia and for procedural sedation. Key pearls: (1) Single dose causes adrenal suppression via 11β-hydroxylase inhibition; avoid continuous infusion or repeated doses. (2) Preferred for hemodynamically unstable patients due to minimal cardiovascular depression. (3) High incidence of myoclonus and pain on injection; pretreat with opioid or benzodiazepine to reduce myoclonus. (4) Contraindicated in porphyria. (5) Rapid onset (30-60 sec) and short duration (3-5 min) limit use to induction only.
This medication will cause you to feel very sleepy and lose consciousness quickly.,You may experience a burning or stinging sensation at the injection site; this is common.,Do not drive, operate machinery, or make important decisions for at least 24 hours after receiving this medication.,You might feel groggy, dizzy, or have a headache after waking up.,Inform your doctor if you have any allergies, especially to eggs, soy, or peanuts.,If you will be receiving this medication for a prolonged period, your doctor will monitor your heart, kidneys, and blood tests.
This medication is given only by a healthcare professional in a hospital or clinic setting.,You may experience involuntary muscle movements (myoclonus) or pain at the injection site.,Tell your doctor if you have adrenal gland problems, porphyria, or if you are pregnant or breastfeeding.,The effects are short-lived; you will be monitored closely during and after administration.,Do not drive or operate machinery for at least 24 hours after receiving this medication.
"Propofol, a general anesthetic, may inhibit CYP2C8, the primary enzyme responsible for rosiglitazone metabolism, leading to decreased clearance and elevated plasma concentrations of rosiglitazone. This interaction can potentiate the hypoglycemic effects of rosiglitazone, increasing the risk of hypoglycemia. Clinical vigilance is warranted when these agents are coadministered, especially in patients with diabetes."
"The combination of propofol and methyldopa can lead to an increased risk of severe hypotension and bradycardia due to additive cardiovascular depressant effects. Propofol causes peripheral vasodilation and direct myocardial depression, while methyldopa reduces sympathetic outflow and depletes catecholamines, enhancing propofol's hemodynamic effects. This interaction may result in profound hypotension, reduced cardiac output, and risk of organ hypoperfusion during anesthesia induction and maintenance."
"Propofol, a GABA-A receptor agonist and general anesthetic, depresses myocardial contractility and reduces systemic vascular resistance, leading to hypotension and bradycardia. Pindolol, a non-selective beta-blocker with intrinsic sympathomimetic activity, can blunt the compensatory tachycardia in response to propofol-induced vasodilation and myocardial depression. Concurrent use may result in additive negative chronotropic and inotropic effects, potentially causing severe bradycardia, hypotension, or reduced cardiac output, especially in patients with compromised cardiac function or hypovolemia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROPOFOL vs AMIDATE, answered by our medical review team.
PROPOFOL is a General Anesthetic that works by Propofol enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to increased chloride conductance, neuronal hyperpolarization, and anesthetic effects. It also inhibits N-methyl-D-aspartate (NMDA) receptors and modulates calcium influx via L-type calcium channels.. AMIDATE is a General Anesthetic that works by AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROPOFOL and AMIDATE depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROPOFOL is: Induction: 2-2.5 mg/kg IV bolus. Maintenance: 25-75 mcg/kg/min IV infusion. For sedation: 25-100 mcg/kg/min IV.. The standard adult dose of AMIDATE is: 0.2-0.6 mg/kg IV bolus for induction of anesthesia.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROPOFOL and AMIDATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROPOFOL is classified as Category A/B. First trimester: Propofol is not associated with major congenital malformations based on limited human data, but animal studies show developmental toxicity at high doses. Second tr. AMIDATE is classified as Category C. Pregnancy Category D. First trimester: Associated with congenital anomalies (e.g., neural tube defects, cardiovascular malformations) based on human data. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.